Camrelizumab, pirfenidone, and chemo for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have triple-negative breast cancer that has spread or come back, and you have at least one tumor that can be measured on scans.
- You have already received first-line chemotherapy plus a PD-1/PD-L1 inhibitor for advanced disease and had a complete or partial response, or stable disease for at least 3 months.
- Your liver, kidney, and blood cell counts are within a certain range (your doctor will check).
- Your heart function is good (normal ejection fraction and a normal ECG).
- You are willing to use effective birth control if you could become pregnant, and have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (camrelizumab), a chemotherapy drug (nab-paclitaxel), and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if adding the allergy medicine helps the treatment work better.
This trial tests if adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can improve outcomes for women with early or locally advanced triple-negative breast cancer. It is for those who haven't had treatment yet and are candidates for surgery.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.